Gaurav is a co-inventor of Piezo’s novel platform and founding CEO of Piezo Therapeutics. Prior to Piezo, he’s served in a variety of roles at Moelis and Company, Capital One, and Elevance Health. He’s a published scientist with a background in drug delivery and synthetic biology. He holds a BS in Industrial and Systems Engineering from Georgia Institute of Technology.

Dr Shawn Fu is currently the Head of CorpDev and Strategy at SonoThera, a venture backed non-viral, ultrasound based gene therapy company. Prior to joining SonoThera, Shawn was a Vice President at Vertex Ventures HC focusing on platform technologies and genetic medicines where he led investments and held board positions across both biotech & medtech opportunities, including, among others, SonoThera, Allay Therapeutics, and SpyGlass Therapeutics. Previously, Shawn also served as Vice President on JP Morgan’s Equity Research desk covering large / SMid Cap Biotech.

Dr Fu obtained his medical degree at UT Southwestern Medical School and his bachelor’s in biology/economics at Duke University.

Jaspreet Arora, PhD, is currently the Director of Business Development at Seran. He has 8 years' experience in drug product development with a recent NDA submission and approval for Leqselvi (Deuruxolitinib). He has early to late-stage experience including commercial readiness and IND/NDA writing. His oral solid dosage form expertise includes formulation and analytical characterization with a focus on material science. Previously Jaspreet worked for Concert Pharma (acquired by Sun Pharma) and Lonza-Bend (Bend Research). Jaspreet has a PhD in Chemical Engineering from Tulane University and a bachelor’s degree in biotechnology from Panjab University. Jaspreet applies his technical experience and training to understand client problem statements and support tailored solutions that fit clients' needs.

Yogev Debbi is the co-founder and CEO of Mana.bio. Previously, after working for years at the tech industry at Intel Corporation (Nasdaq: INTC), he co-founded and was the COO of Genome Compiler, a software gene editing company which was acquired by Twist Bioscience (Nasdaq: TWST), where he then led Twist's Israel R&D center through its IPO. Yogev brings deep expertise in launching and scaling successful bioengineering startups. As a repeat entrepreneur, Yogev is excited about the integration of software and biology and he is focused on leveraging the integration of the two fields to create disruptive technologies to positively impact human health.

Rick Aldridge, MBChB is a Managing Director in Lazard’s Global Healthcare team focused on the Life Sciences Sector.

He joined Lazard in 2015 from Bank of America Merrill Lynch where he was an equity research analyst in the European Pharmaceutical team with lead coverage in the mid-cap biopharma space. The team was top-ranked in the Institutional Investor survey in 2013, 2014 and 2015.

Dr Aldridge is a Chartered Accountant (CA), Chartered Tax Advisor (CTA) and a member of the CFA institute. He holds an MBChB (Medicine) from the University of Edinburgh and a Masters (Dist) in Economic History from the University of Glasgow.

Carl Gordon, PhD, CFA is a Managing Partner and leads OrbiMed’s private equity team. Dr Gordon joined OrbiMed’s predecessor firm in 1995 and was a founding General Partner of OrbiMed in 1998. He did his undergraduate work at Harvard (AB, Chemistry & Physics, 1987), worked at the biotechnology company Imclone Systems (1987-1988), then attained a PhD in Biology from MIT (1993), and was a Postdoctoral Fellow at the Rockefeller University (1993-1995). Carl has been fortunate to have been on the Forbes Midas list of top venture capital investors multiple times. He has founded and invested in numerous biotechnology companies and served on many public and private company boards. When considering investments, Dr Gordon looks for innovative technology and creative management teams and believes the key to success is a combination of integrity, hard work, and passion.

TBA

Dr Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams and drug development consultants, Andy is responsible for driving efficiency and innovation within our scientific organization, both to better serve our customers and drive growth for the Company. Andy has over 15 years of experience in the pharmaceutical and drug delivery industry and is a member of the Academy of Pharmaceutical Scientists of Great Britain. Additionally, Andy has served on the board of directors of the Controlled Release Society, most recently as secretary.

Prior to joining Quotient Sciences, Andy was Director of Novel Drug Delivery Technologies at Ipsen. He holds a Ph.D. in Tissue Engineering and a Bachelor of Pharmacy, both from the University of Nottingham.

Catherine Hines, PhD is the Executive Director and Head of Clinical Imaging at GSK. The mission of GSK’s clinical imaging group to apply, seek, and develop impactful imaging biomarkers for informed clinical decision making. Dr Hines’ organization is responsible for enabling single-site exploratory or enabling imaging studies as well as registrational and multicenter imaging studies for all disease indications. In order to deliver future endpoints and biomarkers, Dr Hines and her team actively anticipate and develops imaging solutions through collaborations with external consultants, academic institutions, and CROs to meet the varied needs of GSK. Current active areas of engagement reside in imaging of neurodegeneration, ImmunoPET, analytics and data re-use; and enhancing relationships within and external to GSK.

Prior to joining GSK, Dr Hines led a multimodality preclinical imaging group within Translational Medicine, where she also was an MRI physicist supporting various MRI and CT applications throughout the Merck pipeline, with emphasis on Safety Assessment, and cardiac and abdominal imaging.

Dr Hines obtained her PhD in Biomedical Engineering and was a Post-Doctoral Fellow in Radiology at the University of Wisconsin-Madison. She has co-led or initiated multiple consortia, including those for DART, IMI, and Parkinson’s Disease, led internship and co-op programs to foster diversity and inclusion efforts, is an active member of the International Society of Magnetic Resonance in Medicine (ISMRM), and is a reviewer for multiple NIH grant programs.